RxDoctor Payments Data

Elsi Diaz, MD

Family Medicine · Sahuarita, AZNPI 1487972477

Payments from drug & device makers

$1,026in general payments, 2019–2025

Across 41 payments — averaging $25.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$301
  • Sumitomo Pharma America, Inc.$134
  • Amgen$97
  • Novo Nordisk$94
  • AstraZeneca$85
  • Abbott$62
  • plus $251 from 8 others

What the payments were for

  • Food & beverage$1,026100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,026 in reported general payments places this provider in the 70th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$68,056
Medicare patients
234
Services billed
955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide61$111,887
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$76,424
MounjaroTirzepatide32$56,599
XareltoRivaroxaban38$50,515
JanuviaSitagliptin Phosphate29$49,643
OzempicSemaglutide26$45,004
Bydureon BciseExenatide Microspheres26$44,643
EliquisApixaban32$41,566
JardianceEmpagliflozin21$33,595
FarxigaDapagliflozin Propanediol30$31,030
LinzessLinaclotide17$25,681
ProliaDenosumab14$24,508
SymbicortBudesonide/Formoterol Fumarate16$9,532
Lantus SolostarInsulin Glargine,hum.Rec.Anlog63$6,769
Omeprazole238$4,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$301$76,42460 claims
MerckJanuvia$60$49,64329 claims
Novo NordiskOzempic$94$45,00426 claims
PfizerEliquis$30$41,56632 claims
AstraZenecaFarxiga, Symbicort$85$40,56246 claims
AbbVieLinzess, Synthroid$16$28,46563 claims
AmgenProlia$97$24,50814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Sahuarita

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →